VAERS Explorer
Back to explore

Report #2859894

Received Sep 19, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
MO
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
IPVPOLIO VIRUS, INACT. (IPOL)SANOFI PASTEURUNK—OT

Symptoms (2)

No adverse eventProduct storage error

Symptom narrative

IPOL maximum/minimum temperature reached: 47.426°F / 8.57°C/ duration of temperature excursion: 1 Hour with no reported adverse event; Initial information received on 16-Sep-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves an unknown age and unknown gender patient who received IPV (VERO) [IPOL] post excursion with maximum/minimum temperature reached: 47.426°f / 8.57°c/ duration of temperature excursion: 1 hour with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received an unknown dose of suspect punctured Ipv (Vero), Suspension for injection (lot number, expiry date and strength not reported) via unknown route in unknown administration site for immunization, post excursion with maximum/minimum temperature reached: 47.426°f / 8.57°c/ duration of temperature excursion: 1 hour with no reported adverse event (product storage error. Information on the batch number was requested corresponding to the one at time of event occurrence. Reportedly, Human error was involved, reason for excursion: transportation and product was used. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.